Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

Inclusion Criteria

• •1. Willing to sign the informed consent, and willing to attend follow-up visits;
• •2. Age ≥ 18;
• •3. Type I or Type II diabetes mellitus with macular thickening secondary to DME involving the center of the fovea;
• •4. CST ≥ 300 μm in the study eye at Screening;
• •5. BCVA ETDRS letters between 19 and 73;
• •6. Participants must have received anti-VEGF therapy within 12 months prior to screening and demonstrated a meaningful response;
• •7. Male subjects whose partner is a fertile female or female subjects who are fertile, agree to take effective contraceptive measures from the screening period until the last follow-up.